Clinical Trial Update: Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on adjuvant pembrolizumab for N2-positive stage IIIA non-small cell lung cancer; the current status of the trial is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Samsung Medical Center | Conditions: Stage IIIA Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN